Pharma: Clinic Roundup

• Merck & Co. Inc., of Whitehouse Station, N.J., reported data from two pivotal Phase III trials of suvorexant in insomnia at SLEEP 2012, the annual Meeting of the Associated Professional Sleep Societies. The orexin receptor antagonist reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at three months, compared to placebo.